Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease

C Alex Wiles; Nisha B Shah; Jake Bell; Baldeep S Pabla; Elizabeth A Scoville; Robin L Dalal; Dawn B Beaulieu; David A Schwartz; Sara N Horst

doi:10.1093/crocol/otab075

Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease

Crohns Colitis 360. 2021 Oct 23;3(4):otab075. doi: 10.1093/crocol/otab075. eCollection 2021 Oct.

Authors

C Alex Wiles¹, Nisha B Shah², Jake Bell², Baldeep S Pabla³, Elizabeth A Scoville³, Robin L Dalal³, Dawn B Beaulieu³, David A Schwartz³, Sara N Horst³

Affiliations

¹ Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Vanderbilt University Medical Center, Vanderbilt Specialty Pharmacy, Nashville, Tennessee, USA.
³ Department of Gastroenterology, Hepatology, & Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Abstract

Background: Tofacitinib has been approved for moderate-to-severe ulcerative colitis and studied in Crohn's disease. Understanding medication adherence to oral medications in severe disease is essential.

Methods: We retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Adherence was measured by proportion of days covered.

Results: Sixty-three patients were identified. All patients failed at least one prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn's disease. Significant clinical and endoscopic response was seen.

Conclusion: Adherence was high in a cohort with highly refractory disease.

Keywords: Crohn’s disease; adherence; tofacitinib; ulcerative colitis.